

Pfizer Quality Improvement RFP

Pathological diagnosis and Immunohistochemistry biomarker assessments of Breast Cancer

Competitive Grant Program – using Internal Review Process

Overview



This competitive program seeks to improve Breast cancer pathological diagnostic capabilities, support HCPs in making evidence-based disease management decisions in a rapidly evolving treatment landscape.”

Geographic Scope/Location of Project



Ghana

Project Types and Area of Interest



- Improving breast cancer pathological diagnosis practices, pre-treatment diagnostic accuracy and capability for more precise treatment initiation.
- Utilizing tools/resources to reduce barriers and promote Immunohistochemistry diagnosis and breast cancer biomarkers identification.

Key Milestones



- Application submission deadline: **June 30, 2024**
- Anticipated decision notification date: **July 30 2024**
- Anticipated project start date: **October, 2024**

Funding Range and Project Length



Individual projects requesting up to \$50,000 USD will be considered.

I. Eligibility

Geographic Scope/Location of Project:

- Ghana

Applicant Eligibility Criteria

- The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations; government agencies; and other entities with a mission related to healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions / organizations / associations, are encouraged. Please note all partners must have a relevant role and the requesting organization must have a key role in the project.
- The applicant must be the Project Lead/Principal Investigator (PI) or an authorized designee of such individual (e.g., Project Lead/PI's grant/research coordinator).
- The Project Lead/PI must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.

II. Requirements

Date RFP Issued

- May 17, 2024

Clinical Area

- Breast Cancer

Specific Area of Interest for this RFP:

- Projects that will be considered for Pfizer support will focus on:

Addressing gaps in the pathological testing of breast cancer, including:

- Capacity to identify hormone receptor status, Human epidermal growth factor receptor 2 status and Ki-67 through immunohistochemistry (IHC).
- Development of protocols and procedures for a sustainable IHC laboratory.
- Use of Pathological testing to better inform appropriate treatment selection options for patients with breast cancer.

Increase the understanding of the risk factors associated with inaccurate pathologic diagnosis of breast cancer to:

- Obtain a complete and timely histopathological review to guide clinical care.
- Better equip physicians to utilize breast cancer biomarkers in the management of patients with breast cancer.
- Improve pre-treatment diagnostic accuracy and capability for more precise treatment

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered. Projects that involve the creation of a new Registry or support for an existing Registry are also out of scope.

Target Audience

- Healthcare professionals focused on diagnosis and management of breast cancer (e.g., pathologists, oncologists, specialty nurses, lab technicians, radiologists)

Expected Approximate Monetary Range of Grant Applications:

- Individual projects requesting up to \$ 50,000 USD will be considered.
- The estimated total available budget related to this RFP is \$100,000.00 USD.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.
- The grant amount to be funded will depend upon the evaluation of the proposal and costs involved and will be stated clearly in the approval notification.

Key Dates:

- RFP release date: May 17, 2024
- Grant Application due date: June 30, 2024 (Please note the deadline is 23:59 CET)
- Anticipated Grant Award Notification Date: July 30, 2024
- Grants will be distributed following a fully executed agreement.
- Anticipated Project Start and End Dates: from September 2024 for a maximum duration of 24 Months.

How to Submit:

Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.

- Please go to www.cybergrants.com/pfizer/QI and sign in. First-time users should click "Create your password". [Note: there are individual portals for each grant application type. Please be sure to use the URL above.]
- Click the "Start a New Quality Improvement Application" button.
- In the application:
 - For the question "Competitive Grant?" select Yes
 - Select the following Competitive Grant Program Name: **2024 ONC Ghana Pathology Breast Cancer QI**
 - Select the following Primary Area of Interest: Oncology- Breast- QI

- Requirements for submission:
Complete all required sections of the online application and upload your project proposal (see Appendix) in the Full Proposal Submission field.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

Questions:

- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Rehab Elsaie (Rehab.Z.Elsaie@pfizer.com), with the subject line “2024 ONC Ghana Pathology Breast Cancer QI.”

Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
- Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms 4 before proceeding with submission of your application as they will need to be accepted in their entirety.
- Payment will only be made to requesting institution.

Review and Approval Process

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

About Pfizer Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the practice gaps as outlined in the specific RFP.

For all independent quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.

Appendix

Quality Improvement Project Full Proposal

Applications will be accepted via the online portal listed in the [How to Submit](#) section. Full Proposal documents should be no longer than 10-15 pages in length (12-point font and 1-inch margins) excluding Organization Detail and References. When uploading your Full Proposal please ensure it addresses the following sections:

Goals and Objectives

- Briefly state the overall goal of the project. Also describe how this goal aligns with the focus of the RFP and the goals of the applicant organization(s).
- List the overall objectives you plan to meet with your project both in terms of learning and expected outcomes. Objectives should describe the target population as well as the outcomes you expect to achieve as a result of conducting the project.

Assessment of Need for the Project

- Please include a quantitative baseline data summary, initial metrics (e.g., quality measures), or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area. Describe the source and method used to collect the data. Describe how the data was analyzed to determine that a gap existed. If a full analysis has not yet been conducted, please include a description of your plan to obtain this information.

Target Audience

- Describe the primary audience(s) targeted for this project. Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

Project Design and Methods

- Describe the planned project and the way it addresses the established need.
- If your methods include educational activities, please describe succinctly the topic(s) and format of those activities.

Innovation

- Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects or materials already developed.
- Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.

Evaluation and Outcomes

- In terms of the metrics used for the needs assessment, describe how you will determine if the practice gap was addressed for the target group. Describe how you expect to collect and analyze the data.
- Quantify the amount of change expected from this project in terms of your target audience.
- Describe how the project outcomes will be broadly disseminated.

Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.

Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.

Organization Detail

- Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.

Budget Detail

- The budget amount requested must be in U.S. dollars (USD).
- While estimating your budget please keep the following items in mind:
 - General organizational running costs such as legal fees, insurance, heating, and lighting etc. should be included in an Institutional Overhead (if required). These costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.
 - The inclusion of overhead costs cannot cause the amount requested to exceed the budget limit set forth in the RFP.
 - Pfizer does not provide funding for capital purchases (infrastructure expenses such as equipment, purchases of software or software licenses, technology or bricks and mortar). Equipment hire/leasing is acceptable and may be included in project budget.
 - It should be noted that grants awarded through GMG cannot be used to purchase Pfizer therapeutic agents (prescription or non-prescription).
- Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects. Please [click here](#) for details.